Florfenicol impairs the immune responses to vaccination against foot-and-mouth disease in mice.
Florfenicol is a new type of broad-spectrum antibacterial that has been used in veterinary clinics. It showed immunosuppressive activity on the immune responses to vaccination against foot-and-mouth disease virus (FMDV) serotype O in mice. In the present study, BALB/c mice were immunized subcutaneously with FMDV serotype O antigen on days 1 and 14. Beginning on day 21, mice were treated with a single daily oral dose of florfenicol (50, 100, and 200 mg/kg) for seven consecutive days. On day 28, blood samples were collected to analyze FMDV-specific immunoglobulin G (IgG), IgG1, and IgG2b antibodies, and splenocytes were harvested to assess lymphocyte proliferation, CD3(+) T- and CD19(+) B-lymphocyte subsets. The results presented here demonstrated that florfenicol not only significantly suppressed concanavalin A-, lipopolysaccharide-induced splenocyte proliferation but also decreased the percentage of CD19(+) B-cells in a dose-dependent manner and suppressed CD3(+) T-cell at high doses. Moreover, FMDV-specific IgG, IgG1, and IgG2b antibody levels in FMDV-immunized mice were reduced by florfenicol. These results suggested that florfenicol could suppress humoral and cellular immune responses to vaccination against foot-and-mouth disease (FMD) in mice.